Table 1 Primary characteristics of the trials included in the study.

From: A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: A systematic review and meta-analysis

 

Serruys 2013

Chevalier 2015

Zhang 2015

Grundeken 2016

Jaguszewski 2016

BP-BES/DP-DES

BP-BES/DP-DES

BP-BES/DP-DES

BP-BES/DP-DES

BP-BES/DP-DES

Journal

JACC Cardiovasc Interv

Euro Intervention

Heart

Catheter Cardiovasc Interv

Catheter Cardiovasc Interv

BP-BES

BES BioMatrix Flex

BES Nobori

BES Biomatrix Flex

BES Biomatrix Flex

BES Biomatrix/Nobori

DP-DES

SES Cypher Select

PES Taxus Liberte/Express

SES Cypher Select

SES Cypher Select

EES Xience V/ZES Resolute Integrity

Sample size

857/850

238/125

280/293

258/239

369/1178

Age, years

64.6 ± 10.8/64.5 ± 10.7

63.2 ± 10.6/62.9 ± 10.0

62.9 ± 11.7/62.8 ± 11.7

65.1 ± 10.3/64.2 ± 11.0

62.3 ± 0.7/62.8 ± 0.3

Male, %

75.0/74.6

72.7/68.0

76.8/71.7

70.9/74.5

78.6/79.4

Diabetes (%)

26.0/22.5

16.8/27.2

50.5/59.2

65.4/57

15.7/18.1

ACS (%)

54.8/55.7

24.37/26.4

100/100

52.3/55.6

100/100

LVEF (%)

55.9 ± 11.3/55.4 ± 12.4

N/A

51.5 ± 10.1/51.4 ± 11.8

N/A

52.4 ± 0.7/52.7 ± 0.4

Multivessel disease (%)

24.2/20.7

N/A

N/A

N/A

54.2/56.2

SYNTAX score

13.2/13.3

N/A

14.7 ± 8.8/15.3 ± 8.7

16.9 ± 8.3/16.8 ± 8.9

N/A

No. of stents used per patient

1.3/1.3

N/A

2.2/2.2

N/A

N/A

Total stent length, mm per patient

24.7/24.6

N/A

26.6/27.9

N/A

N/A

  1. BP-BES = biodegradable polymer biolimus-eluting stents, DP-DES = durable polymer drug-eluting stents, ACS = acute coronary syndrome, LVEF = left ventricular ejection fraction, N/A = not applicable.
Back to article page